Last Wednesday, diabetes researchers and advocates from around the country convened in Washington, DC, for an FDA hearing on the Artificial Pancreas with the aim of making this pipe dream a reality. The point of the hearing was to allow JDRF and other stakeholders — researchers, industry reps, and patients — a chance to provide input on the Artificial Pancreas Project, in particular “recommendations to ensure the safe and effective testing of artificial pancreas technology…Read more »
There were a number of encouraging news announcements this week here in Florida about progress on the JDRF’s Artificial Pancreas Project. The most prominent of those is today’s unveiling of the results of the STAR 3 Trial (Sensor-Augmented Pump Therapy for A1C Reduction) that showed adults, teens and children achieving a 4x reduction in A1C levels using this tech-heavy therapy versus patients on injections.
The STAR study, sponsored by Medtronic, was conducted at 30 clinics…
Get ready for a slew of diabetes news announcements, because the ADA’s huge annual conference starts today!
I’ll be on an airplane pretty much all day (Friday) heading out to Orlando to cover this conference live, although I must warn you: it’s quite overwhelming. Running around the 450,000 square-foot convention center trying to see every diabetes company represented in the enormous exhibit halls while hundreds of symposia and other talk sessions are happening simultaneously is…Read more »
When the JDRF recently announced its newest artificial pancreas push — a partnership with Animas and Dexcom to actually develop a commercial product — head of the project Aaron Kowalski kindly agreed to answer reader questions here.
Today, I bring you those answers, direct “from the horses’ mouth,” as it were.
Q) How much more advanced will this be than the Medtronic Paradigm Veo system launched in Europe, which stops insulin delivery for…
Very big news in the diabetes world today, Folks: the Juvenile Diabetes Research Foundation (JDRF) has announced a partnership with insulin pump makers Animas Corp. (a Johnson & Johnson company) to actually start building the first ready-for-market artificial pancreas, i.e. “a fully automated system to dispense insulin … based on real-time changes in blood sugar levels.” DexCom will provide the continuous glucose monitoring (CGM) technology for the new system being developed.
I was fortunate to…